BIMODAL MOLECULAR WEIGHT HYALURONATE FORMULATIONS AND METHODS FOR USING SAME

Abstract: Compositions and methods useful for protecting human or animal eye cell layers and tissues exposed to trauma, e.g., during surgery, are disclosed. In one embodiment, the method comprises administering a protective amount of an ophthalmically acceptable aqueous composition containing a first alkali metal and/or alkaline earth metal hyaluronate fraction having a molecular weight of at least about 300,000, for example, in the range of about 500,000 to about 750,000, and a second alkali metal and/or alkaline earth metal hyaluronate fraction having a molecular weight of less than about 200,000, for example, in the range of about 25,000 to about 175,000, to eye cell layers and tissues prior to the exposure to the trauma.

Description: BIMODAL MOLECULAR WEIGHT HYALURONATE FORMULATIONS AND METHODS FOR USING SAME Related Application This application is a continuation-in-part of co- pending application Serial No. 621,290 filed November 30, 1990. Background of the Invention This invention relates to compositions and methods useful to protect human or animal eye cell layers and tissue subject to exposure to trauma. More particularly, the invention relates to compositions and methods involving hyaluronate fractions having differing molecular weights for protecting eye cell layers and tissues exposed to trauma, for example, during surgery. When the natural lens of the eye becomes hazy or clouded, surgery is often indicated to remove the impaired lens. The current trend in such surgery is toward breaking the lens into a plurality of particles and then removing the particles, e.g., using the conventional phacoemulsification procedure. The use of a protective agent, in particular a viscoelastic fluid, that adheres to and protects the corneal endothelium during the surgical procedure is highly beneficial. Fluids containing high molecular weight range hyaluronates, that is hyaluronates having weight average molecular weights over 750,000, do not provide entirely acceptable adhesion to and/or protection of the corneal endothelium during certain surgical procedures. An example of such a fluid is that sold by Pharmacia Ophthalmics of Monrovia, California under the trademark Healon. Formulations which include hyaluronic acid having a molecular weight of at least about 750,000, and preferably at least about 1,200,000 are disclosed in Balazs U.S. Patent 4,141,973. Such formulations, which are not described in this patent as including any lower molecular weight hyaluronic acid, are disclosed as being useful in a number of applications, such as in the replacement of the aqueous humor after various intraocular surgical procedures, and as a biological prosthesis in the anterior chamber after cataract surgery. Another formulation which includes high molecular weight hyaluronate (molecular weight of 1x10 to 4.5x10 ) is that disclosed in Balazs U.S. Patent 4,303,672. The cosmetic formulations of this patent also include a low molecular weight hyaluronate fraction (molecular weight of 10,000 to 200,000) and protein in an amount ranging from 50% to 400% the weight of the hyaluronate. Such compositions are taught as having emollient, moisturizing, elasticizing and lubricating properties where applied to the skin. Such protein-containing hyaluronate compositions are not ophthalmically acceptable and would not be useful as protective agents in eye surgery. Bracke et al U.S. Patent 4,517,295 discloses hyaluronic acid having an average molecular weight of about 55,000 which is produced from bacterial sources. Such hyaluronic acid is disclosed as having potentially significant use as an eye drop ingredient and as an ingredient of cosmetic formulations, as well as being useful in post-surgical applications for reducing complications due to fibrotic response and/or adhesion formation. This patent does not disclose the use of such hyaluronic acid as a protective agent in eye surgery. Other formulations incorporate combinations of different materials, such as sodium hyaluronate and chondroitin sulfate. This type of product is described in Australian Patent 555,747. A product for use in providing protection during eye surgery and including sodium hyaluronate and chondroitin sulfate is that sold by Alcon Surgical, Inc. of Forth Worth, Texas under the trademark Viscoat. Sources of chondroitin sulfate often include significant amounts of protein which need to be removed, using relatively complex and expensive separation techniques, before the purified chondroitin sulfate can be used in the eye. There continues to be a need for compositions useful in protecting ocular or eye cell layers and tissues exposed to trauma, in particular trauma involved in ophthalmic surgical procedures. Summary of the Invention New compositions and methods useful to protect human or animal ocular or eye cell layers and tissues subject to exposure to trauma have been discovered. The present ophthalmically acceptable compositions, which include two distinct molecular weight fractions of alkali metal and/or alkaline earth metal hyaluronates, have been found to provide a substantial degree of protection against trauma, such as that trauma which occurs during eye surgery, in particular eye surgery such as the removal of a diseased natural lens. The present compositions, which are based on hyaluronate fractions, are relatively easy to manufacture and to obtain governmental regulatory approval on, in comparison to compositions which include two or more significantly dissimilar adhesion/protective components. In one embodiment, the present ophthalmically acceptable compositions, in particular in the form of solutions, comprise water, a first alkali and/or alkaline earth metal hyaluronate fraction having a molecular weight of at least about 300,000 and a second alkali and/or alkaline earth metal hyaluronate fraction having a molecular weight of less than about 200,000. The first hyaluronate fraction preferably has a mole ular weight in the range of about 350,000 to about 800,000, more preferably in the range of about 500,000 to about 750,000. The second hyaluronate fraction preferably has a molecular weight in the range of about 25,000 or about 35,000 to about 150,000 or about 175,000. The second hyaluronate fraction may have a molecular weight in the range of about 30,000 to about 100,000. Preferably, the compositions are essentially non-pyrogenic and protein-free. The ophthalmically acceptable compositions may, and preferably do, include at least one buffer component in an amount effective to control the pH of the composition and/or at least one tonicity adjuster component in an amount effective to control the osmolality of the composition. More preferably, the present compositions include both a buffer component and a tonicity adjuster component. The ophthalmically acceptable compositions of the present invention are preferably sterile. In another embodiment of the present invention, methods to protect human or animal eye cell layers and tissues subject to exposure to trauma are provided. These methods comprise administering an amount effective to protect the ocular or eye cell layers and tissues of an ophthalmically acceptable composition, such as described herein, to the cell layers and tissues prior to exposure to trauma. In a particularly useful embodiment, methods are provided for removing the natural lens from the eye of a human or animal. These lens removal methods comprise introducing a protective amount of an ophthalmically acceptable composition, such as described herein, into the eye of a human or animal. This introduced composition acts to adhere to and/or protect the eye cell layerπ and tissues, in particular the corneal endotheliu-", in proximity to the natural lens in the eye. The natural lens is caused to break into a plurality of particles, e.g., using a conventional surgical procedure which involves a potentially traumatic force associated with a relatively high degree of turbulence. These particles are removed from the eye. The hyaluronate-containing composition is also removed from the eye. In this manner, the defective natural lens, for example, a natural lens which has developed a cataract condition, is effectively removed from the eye without causing undue trauma or adverse effects to the eye cell layers and tissues in proximity to the natural lens which is removed. The presently useful compositions are relatively easy to administer to the eye, provide a very effective and high degree of protection against the potential trauma of the surgical procedure, and are relatively easy to remove, such as by irrigation/aspiration from the eye, after the protection is no longer needed. In particular, the present compositions are maintained in a protective amount on the eye cell layers and tissues in spite of the relative high degree of turbulence associated with causing the natural lens to break into a plurality of particles and/or removing the lens particles from the eye. Without such protection, lens fragments may impact and damage sensitive cell layers and tissues, such as the corneal endothelium. Detailed Description of the Invention Ophthalmically acceptable compositions, in particular in the form of solutions, comprising water, a first alkali and/or alkaline earth metal hyaluronate fraction having a moderate to high molecular weight and a second alkali and/or alkaline earth metal hyaluronate fraction having a relatively low molecular weight, and preferably at least one buffer component and/or at least one tonicity adjuster component, have been found to provide substantial advantages, e.g., in terms of providing adhesion and/or protection to human or animal cell layers and tissues located in the eye which are exposed to trauma, in particular during surgical procedures. The present compositions also have other properties useful in viscoelastic fluids, such as high viscosity at zero shear, elasticity and pseudoplasticity. The molecular weights noted herein are the weight average molecular weights of the fraction or fractions. This weight average molecular weight can be determined or measured by an indirect method, in particular the limiting viscosity method. The weight average molecular weight may be calculated from the limiting viscosity number by the published equation of Laurent et al, Fractionation of Hyaluronic Acid, Biochimica Et Biophysics Acta, 42, pps 476-485 (1960). Alternately, the weight average molecular weight can be determined using size exclusion chromatography techniques. The first hyaluronate fractions useful in the present invention have moderate to high molecular weights, in particular, molecular weights in the range of at least about 300,000, more particularly in the range of about 300,000 to about 1,000,000. The first hyaluronate fractions preferably have molecular weights in the range of about 350,000 to about 800,000, more preferably about 500,000 to about 750,000. The presently useful second hyaluronate fractions have molecular weights of less than about 200,000, preferably in the range of about 25,000 or about 35,000 to about 150,000 or about 175,000. Second hyaluronate fractions having molecular weights in the range of about 30,000 to about 100,000 are very useful. As is conventional and well known in the art, the first and second hyaluronate fractions can be obtained from various sources, such as rooster combs and other connective tissue, and from bacterial sources, in particular bacterial fermentation. The molecular weight fractions can be obtained using conventional separation procedures. Alternately, high molecular weight hyaluronates can be converted, for example, hydrolyzed, to lower molecular weight hyaluronates, which are then recovered and used. The first hyaluronate fraction and second hyaluronate fraction are each preferably independently selected from the group consisting of sodium hyaluronates, potassium hyaluronates, magnesiumhyaluronates, calciumhyaluronates and mixtures thereof. More preferably, each of these fractions involves the same metal or metals. Sodium hyaluronate fractions are particularly useful. The weight ratio of the first hyaluronate fraction to the second hyaluronate fraction in the presently useful compositions is preferably in the range of about 0.25 to about 4, more preferably about 0.5 to about 2. The concentration of the first hyaluronate fraction in the presently useful compositions is preferably in the range of about 5 mg/ml to about 50 mg/ml, more preferably about 10 mg/ml or about 20 mg/ml to about 40 mg/ml. The present ophthalmically acceptable compositions are preferably essentially free of protein and essentially non-pyrogenic. The present compositions preferably include less than about 0.5% by weight of protein based on the total weight of first and second alkali and/or alkaline earth metal hyaluronates. More preferably, the present compositions have no detectable protein content and no detectable pyrogenicity. The present compositions preferably include a major amount of liquid water, e.g., as a carrier or liquid medium for the hyaluronate fractions. The present ophthalmically acceptable compositions are preferably sterile, in particular prior to being used in the eye. The present compositions preferably include at least one buffer component in an amount effective to control the pH of the composition and/or at least one tonicity adjuster component in an amount effective to control the osmolality of the composition. More preferably, the present compositions include both a buffer component and a tonicity adjuster component. Such components are useful in maintaining the present compositions ophthalmically acceptable so that, for example, the presence of these compositions in the eye do not result in any undue adverse effect or permanent damage to the eye. The use of one or more tonicity adjuster components is particularly important when the composition is to be applied to one or more portions of the cornea. Such tonicity adjuster components act to enhance the compatibility between the composition and the corneal tissue and/or to avoid damage to the corneal tissue. Such buffer components and tonicity adjuster components may be chosen from those which are conventional and well known in the art. Examples of useful buffer components include, but are not limited to, acetate buffers, citrate buffers, phosphate buffers, borate buffers and the like and mixtures thereof. Phosphate buffers are particularly useful. Useful tonicity adjuster components include, but are not limited to, salts, particularly sodium chloride, potassium chloride, any other suitable ophthalmically acceptable tonicity adjuster component and mixtures thereof. The amounts of buffer component and osmolality control component employed are preferably sufficient to maintain the pH of the compositions in the range of about 6 to about 8, more preferably about 7 to about 7.5, and the osmolality of the compositions in the range of about 200 to about 400, more preferably about 250 to about 350, mOsmol/kg, respectively. The present compositions may include one or more other components in amounts effective to provide one or more useful properties and/or benefits to the present compositions. The present compositions are useful in a method for protecting human or animal ocular or eye cell layers and tissues which are subject to being exposed to trauma, for example, during surgery. In one embodiment, the present method comprises administering a protective amount of such a composition to the ocular or eye cell layers and tissues which are subject to exposure to trauma prior to exposure to the trauma. In this manner, such compositions preferably act to adhere to, or at least partially coat, the cell layers and tissues and/or provide protection for such cell layers and tissues from an imposed trauma. The present compositions provide particularly good protection in situations where the trauma or potential trauma to which the eye cell layers or tissues is exposed occurs in a dynamic, turbulent environment, such as during a surgical procedure in which a natural lens to be removed is broken into particles, such as by using the conventional phacoemulsification technique. A specific application in which the present compositions find significant usefulness is in a method for removing the natural lens, e.g., which is diseased, from the eye of a human or animal. In this embodiment, a protective amount of a composition in accordance with the present invention is introduced, such as by being injected, into the eye of a human or animal, for example, through an incision made in the eye. Such compositions can be relatively easily introduced into the eye, for example, using conventional injection cannulas or the like. The composition preferably adheres to at least a portion of the eye cell layers and tissues, in particular the corneal endothelium. in proximity to the natural lens to be removed. With the present composition in place, the natural lens is caused to break into a plurality of particles. One particularly useful approach to breaking up the natural lens is to use a conventional lens emulsification procedure, such as the well known phacoemulsification procedure. Unless the portions of the eye in proximity to the natural lens are provided with protection, the dynamic force used to break up the natural lens and/or the turbulence which often occurs during such lens removal procedures may also damage these other portions of the eye. The use of the present compositions has been found to provide adequate protection for these eye portions, in particular the corneal endothelium, against such potentially traumatic force and/or turbulence. The plurality of lens particles is removed, for example, using a conventional irrigation/aspiration procedure, from the eye. The present hyaluronate- containing composition is also removed, along with the lens particles and/or after further irrigation/aspiration, from the eye. Such removal occurs relatively easily and substantially without detrimentally affecting the remaining portions of the eye. An intraocular lens can then be implanted in the eye, e.g., using a conventional technique, to replace the removed natural lens. After this implantation, the incision in the eye is closed, such as by suturing. The use of the present compositions, as described above, allows for effective removal of the natural lens from the eye without substantially damaging the eye cell layers and tissues in proximity to the natural lens. The following non-limiting examples illustrate certain ' aspects of the present invention. EXAMPLES 1 TO 3 A composition (Composition 1) was prepared by mixing two sodium hyaluronate fractions with a standard phosphate buffered saline solution. This composition included 20 mg/ml of a ' sodium hyaluronate fraction having a weight average molecular weight of about 700,000, and 20 mg/ml of a sodium hyaluronate fraction having a weight average molecular weight of about 50,000. Composition 2 (comparative) was a phosphate buffered saline solution containing 30 mg/ml of a sodium hyaluronate fraction having a weight average molecular weight of about 500,000, and 40 mg/ml of chondroitin sulfate having a weight average molecular weight of about 50,000. Composition 2 is commercially available from Alcon Surgical, Inc., Forth Worth, Texas, and is sold under the trademark Viscoat. Composition 3 (comparative) was a phosphate buffered saline solution containing 10 mg/ml of a sodium hyaluronate fraction having a weight average molecular weight of 3 to 4 million. Composition 3 is commercially available from Pharmacia Ophthalmics, Monrovia, California, and is sold under the trademark Healon. Each of these compositions was tested as follows. Healthy New Zealand white rabbits were selected for surgery. The surgical procedure performed, using conventional techniques, on the eye of the selected rabbit involved anterior capsulotomy, phacoemulsification of the eye's natural lens (using a standard phacoemulsification unit), irrigation/aspiration and intraocular lens implantation. Each of the compositions was loaded into a standard BD Hypack syringe. A 25g cannula was attached to each syringe for the injections. Each rabbit received one (1) fluid sample for each eye prior to the procedure. This fluid was replenished as necessary as the surgical procedure progressed. The surgeon's observations relating to these compositions included the following: Composition 1 was difficult to inject through a 25g cannula. It maintained the anterior chamber well and adhered strongly to the corneal endothelium cells during the phacoemulsification procedure, but was difficult to remove during irrigation/aspiration due to its relatively high viscosity and stickiness. Composition 2 was somewhat easier to inject than Composition 1 and it maintained the chamber approximately the same as Composition 1. Composition 2 coated the corneal endothelium well and was somewhat difficult to remove by irrigation/aspiration. Composition 3 was very easy to inject. However, it did not appear to maintain the anterior chamber as well as Compositions 1 and 2 during the anterior capsulotomy procedure. Furthermore, Composition 3 flushed completely out of the eye upon initiation of phacoemulsification and did not appear to coat either the endothelial cells or the intraocular lens well. Composition 3 was the most readily removed during irrigation/aspiration. These results indicate that Composition 1 provided the desired protection during the phacoemulsification procedure. Such protection was as good as or better than the protection achieved using the other compositions tested. Also, the relatively high viscosity and stickiness of Composition 1 can be reduced by reducing the concentrations of one or both of the sodium hyaluronate components and/or by adjusting the ratio of the different molecular weight sodium hyaluronate components and/or by adjusting the molecular weight of one or both of the sodium hyaluronate components. EXAMPLES 4 TO 8 A composition (Composition 4) was prepared by mixing two sodium hyaluronate fractions with a standard saline solution. This composition included 30 mg/ml of a sodium hyaluronate fraction having a weight average molecular weight of 700,000, and 5 mg/ml of a sodium hyaluronate fraction having a weight average molecular weight of 120,000. The viscosity of Composition 4 was 75,000 centipoises at a shear rate of 1 sec " . A composition (Composition 5) was prepared by mixing two sodium hyaluronate fractions with a standard saline solution. This composition included 25 mg/ml of a sodium hyaluronate fraction having a weight average molecular weight of 700,000, and 10 mg/ml of a sodium hyaluronate fraction having a weight average molecular weight of 120,000. The viscosity of Composition 5 was 45,000 centipoises at a shear rate of l sec-1. A composition (Composition 6) was prepared by mixing two sodium hyaluronate fractions with a standard saline solution. This composition included 20 mg/ml of a sodium hyaluronate fraction having a weight average molecular weight of 700,000, and 30 mg/ml of a sodium hyaluronate fraction having a weight average molecular weight of 120,000. The viscosity of Composition 6 was 20,000 centipoises at a shear rate of 1 sec " . Composition 7 (comparative) was similar to Composition 2. The viscosity of Composition 7 was 45,000 centipoises at a shear rate of 1 sec " . Composition 8 (comparative) was similar to Composition 3. The viscosity of Composition 8 was 45,000 centipoises at a shear rate of 1 sec . Each of these compositions was tested as follows. Healthy New Zealand white rabbits were selected for surgery. The surgical procedure performed, using conventional techniques, on the eye of the selected rabbit involved anterior capsulorhexis, phacoemulsification of the eye's natural lens (using a standard phacoemulsification unit), irrigation/aspiration and intraocular lens implantation. Each of the compositions was loaded into a 3 cc BD syringe. A 27 g cannula was attached to each syringe for the injections. Each rabbit received one (1) fluid sample for each eye prior to the procedure. This fluid was replenished as necessary as the surgical procedure progressed. The surgeon's observations relating to these compositions included the following: Composition 4 injected through a 27 g cannula with some difficulty. It maintained the anterior chamber well during capsulorhexis, and adhered well to the corneal endothelium during the phacoemulsification procedure. This material was removed fairly easily during irrigation/aspiration. Composition 5 injected through a 27 g cannula with some difficulty. It did not maintain the anterior chamber during capsulorhexis as well as Composition 4. Composition 5 adhered well to the corneal endothelium during the phacoemulsification procedure and was removed easily during irrigation/aspiration. Composition 6 was difficult to inject through a 27 g cannula. It maintained the anterior chamber during capsulorhexis approximately the same as Composition 4. Composition 6 adhered well to the corneal endothelium during the phacoemulsification procedure, and was easily removed during irrigation/aspiration. Composition 7 was somewhat easier to inject than Compositions 4 and 5, and was much easier to inject than Composition 6. However, Composition 7 did not maintain the anterior chamber during capsulorhexis as well as either Composition 4 or Composition 6. It maintained the anterior chamber approximately the same as Composition 5, and adhered about as well to the corneal endothelium during the phacoemulsification procedure as did either Composition 5 or Composition 6. Composition 7 was removed easily during irrigation/aspiration. Composition 8 was very easy to inject. However, it did not maintain the anterior chamber during capsulorhexis as well as any of the other compositions. Composition 8 completely flushed out of the eye upon initiation of phaco¬ emulsification and did not appear to coat the corneal endothelium well. Composition 8 was the most readily removed by irrigation/aspiration. These results indicate that Compositions 4, 5 and 6, in accordance with the present invention, provided superior protection during capsulorhexis and the phacoemulsification procedure relative to Composition 8 which includes a high molecular weight sodium hyaluronate fraction. In addition, the present compositions, that is Compositions 4, 5 and 6, provide substantially as good or better protection than did Composition 7, which includes both a sodium hyaluronate fraction and a chondroitin sulfate fraction. Of course, the present compositions have advantages, for example, in ease of manufacture, relative to Composition 7 which includes two significantly different materials, sodium hyaluronate and chondroitin sulfate. When comparing Compositions 1, 4, 5 and 6 (in accordance with the present invention) with Compositions 3 and 8, the present compositions provide results which are generally superior with respect to compositions containing a single high molecular weight sodium hyaluronate fraction. These results also demonstrate that compositions including a first hyaluronate fraction having a weight average molecular weight in the range of about 500,000 to about 750,000 and a second hyaluronate fraction having a weight average molecular weight in the range of about 25,000 or about 35,000 to about 150,000 or about 175,000 provide substantially comparable results. For example, changing the weight average molecular weight of the second hyaluronate fraction from 50,000 (Composition 1) to 120,000 (Compositions 4, 5 and 6) did not result in any substantial change in the beneficial properties achieved using the present compositions. The first hyaluronate fraction tested, that is having a weight average molecular weight of 700,000 is representative of hyaluronates having weight average molecular weights in the range of about 500,000 to about 750,000, That is, no substantial difference in composition performance would occur by changing the weight average molecular weight of the first hyaluronate fraction within the range about 500,000 and about 750,000. In other words, the data presented in these Examples is representative of compositions including a first hyaluronate fraction having high molecular weight average molecular weight in the range of about 500,000 to about 750,000 and a second hyaluronate fraction having a weight average molecular weight in the range of about 25,000 or about 35,000 to about 150,000 to about 175,000. These Examples make clear that the present compositions provide as good or better performance than the current commercially available materials, as set forth in Compositions 2, 3, 7 and 8. In particular, the present compositions provide improved performance relative to compositions which include only a single high molecular weight hyaluronate fraction, that is Compositions 4 and 8. This result is clearly unexpected and provides substantial benefits, for example, in terms of improved performance while being relatively easy to manufacture and to control the quality of, and to obtain governmental regulatory approval on. While this invention has been described with respect to various specific examples and embodiments, it is to be understood that the invention is not limited thereto and that it can be variously practiced within the scope of the following claims.

Claims: WHAT IS CLAIMED IS: 1. A method to protect human or animal eye cell layers and tissues subject to exposure to trauma which comprises administering a protective amount of an ophthalmically acceptable aqueous composition comprising water, a first metal hyaluronate fraction having a weight average molecular weight in the range of about 500,000 to about 750,00, and a second metal hyaluronate fraction having a weight average molecular weight in the range of about 25,000 to about 175,000 to said eye cell layers and tissues prior to said exposure to said trauma, said first metal hyaluronate fraction and said second metal hyaluronate fraction each being independently selected from the group consisting of alkali metal hyaluronates, alkaline earth metal hyaluronates and mixtures thereof. 2. The method of claim 1 wherein said ophthalmically acceptable aqueous composition further includes at least one buffer component in an amount effective to control the pH of said ophthalmically acceptable aqueous composition and at least one tonicity adjuster component in an amount effective to control the osmolality of said ophthalmically acceptable aqueous composition. 3. The method of claim 2 wherein said opthalmically acceptable aqueous composition has a pH in the range of about 6 to about 8, and an osmolality in the range of about 200 to about 400 mOsmol/kg, and said second metal hyaluronate fraction has a weight average molecular weight in the range of about 35,000 to about 150,000. 4. The method of claim 1 wherein said second metal hyaluronate fraction has a weight average molecular weight in the range of about 30,000 to about 100,000. 5. The method of claim 1 wherein said first metal hyaluronate fraction and said second metal hyaluronate fraction each is independently selected from the group consisting of sodium hyaluronates, potassium hyaluronates, magnesium hyaluronates, calcium hyaluronates and mixtures thereof. 6. The method of claim 1 wherein said first metal hyaluronate fraction is a first sodium hyaluronate fraction and said second metal hyaluronate fraction is a second sodium hyaluronate fraction. 7. The method of claim 1 wherein the weight ratio of said first metal hyaluronate fraction to said second metal hyaluronate fraction in said ophthalmically acceptable aqueous composition is in the range of about 0.25 to about 4, said first metal hyaluronate fraction is present in said ophthalmically acceptable aqueous composition in a concentration in the range of about 5 mg/ml to about 50 mg/ml. 8. The method of claim 1 wherein said ophthalmically acceptable aqueous composition is sterile and essentially non-pyrogenic prior to being administered. 9. A method for removing the natural lens from the eye of a human or animal which comprises: introducing a protective amount of an opthalmically acceptable aqueous composition into said eye of said human or animal, said composition comprising water, a first sodium hyaluronate fraction having a weight average molecular weight in the range of about 500,000 to about 750,000, and a second sodium hyaluronate fraction having a weight average molecular weight in the range of about 25,000 to about 175,000, said composition adht.w ing to at least one portion of the eye in proximity to 3did natural lens in said eye; causing said natural lens to break int^ a plurality of particles; removing said plurality of particles; and removing said composition from said eye. 10. The method of claim 9 wherein said ophthalmically acceptable aqueous composition furt er includes at least one buffer component in an amount effective to control the pH of said ophthalmica ; , • acceptable aqueous composition and at least one tonici'v adjuster component in an amount effective to control thr> osmolality of said ophthalmically acceptable aqueou - composition. 11. The method of claim 10 wherein sai ; opthalmically acceptable aqueous composition has a pH i^ the range of about 7 to about 7.5, and an osmolality i < the range of about 250 to about 350 mOsmol/kg, and saic second sodium hyaluronate fraction has a weight average molecular weight in the range of about 35,000 to abou: 150,000. 12. The method of claim 9 wherein the weight ratio of said first sodium hyaluronate fraction to said second sodium hyaluronate fraction in said ophthalmically acceptable aqueous composition is in the range of about 0.25 to about 4. 13. A composition comprising water, a first metal hyaluronate fraction having a weight average molecular weight in the range of about 500,000 to about 750,000 and a second metal hyaluronate fraction having a weight average molecular weight in the range of about 25,000 to about 175,000, said composition being ophthalmically acceptable, and said first metal hyaluronate fraction and said second metal hyaluronate fraction each being independently selected from the group consisting of alkali metal hyaluronates, alkaline earth metal hyaluronates and mixtures thereof. 14. The composition of claim 13 which further comprises at least one buffer component in an amount effective to control the pH of said composition and at least one tonicity adjuster component in an amount effective to control the osmolality of said composition. 15. The composition of claim 14 wherein said composition has a pH in the range of about 6 to about 8, and an osmolality in the range of about 200 to about 400 mOsmol/kg, and said second metal hyaluronate fraction has a weight average molecular weight in the range of about 35,000 to about 150,000, said composition being sterile and essentially non-pyrogenic. 16. The composition of claim 13 wherein said second metal hyaluronate fraction has a molecular weight in the range of about 30,000 to about 100,000. 17. The composition of claim 13 wherein said first metal hyaluronate fraction and said second metal hyaluronate fraction are each independently selected from the group consisting of sodium hyaluronates, potassium hyaluronates, magnesium hyaluronates, calcium hyaluronates and mixtures thereof. 18. The composition of claim 13 wherein said first metal hyaluronate fraction is a first sodium hyaluronate fraction and said second metal hyaluronate fraction is a second sodium hyaluronate fraction. 19. The composition of claim 13 wherein the weight ratio of said first metal hyaluronate fraction to said second metal hyaluronate fraction in said composition is in the range of about 0.25 to about 4. 20. The composition of claim 19 wherein said first metal hyaluronate fraction is present in said composition in a concentration in the range of about 5 mg/ml to about 50 mg/ml. AMENDED CLAIMS [received by the International Bureau on 26 July 1993 (26.07.93); original claims 1,2,9,10,12-14 amended; other claims unchanged (5 pages)] 1. A method to protect human or animal eye cell layers and tissues subject to exposure to trauma which comprises administering a protective amount of an ophthalmically acceptable aqueous composition comprising 5 water, a first metal hyaluronate fraction having a weight average molecular weight in the range of about 500,000 to about 750,000, and a second metal hyaluronate fraction having a weight average molecular weight in the range of about 25,000 to about 175,000 to said eye cell layers and 10 tissues prior to said exposure to said trauma, said first metal hyaluronate fraction and said second metal hyaluronate fraction each being independently selected from the group consisting of alkali metal hyaluronates, alkaline earth metal hyaluronates and mixtures thereof. 2. The method of claim 1 wherein said ophthalmically acceptable aqueous composition further includes at least one buffer component in an amount effective to control the pH of said ophthalmically 5 acceptable aqueous composition and at least one tonicity adjuster component in an amount effective to control the osmolality of said ophthalmically acceptable aqueous composition, said administering being effective to provide superior protection to said eye cell layers and tissues 10 relative to the protection obtained by administering a similar composition including a single metal hyaluronate fraction having a weight average molecular weight of 3 to 4 million to said eye cell layers and tissues prior to said exposure to said trauma. 3. The method of claim 2 wherein said opthalmically acceptable aqueous composition has a pH in the range of about 6 to about 8, and an osmolality in the range of about 200 to about 400 mOsmol/kg, and said second metal hyaluronate fraction has a weight average molecular weight in the range of about 35,000 to about 150,000. 4. The method of claim 1 wherein said second metal hyaluronate fraction has a weight average molecular weight in the range of about 30,000 to about 100,000. 5. The method of claim 1 wherein said first metal hyaluronate fraction and said second metal hyaluronate fraction each is independently selected from the group consisting of sodium hyaluronates, potassium hyaluronates, magnesium hyaluronates, calcium hyaluronates and mixtures thereof . 6. The method of claim 1 wherein said first metal hyaluronate fraction is a first sodium hyaluronate fraction and said second metal hyaluronate fraction is a second sodium hyaluronate fraction. 7. The method of claim 1 wherein the weight ratio of said first metal hyaluronate fraction to said second metal hyaluronate fraction in said ophthalmically acceptable aqueous composition is in the range of about 0.25 to about 4, said first metal hyaluronate fraction is present in said ophthalmically acceptable aqueous composition in a concentration in the range of about 5 mg/ml to about 50 mg/ml. 8. The method of claim 1 wherein said ophthalmically acceptable aqueous composition is sterile and essentially non-pyrogenic prior to being administered. 9. A method for removing the natural lens from the eye of a human or animal which comprises : introducing a protective amount of an opthalmically acceptable aqueous composition into said eye of said human or animal, said ophthalmically acceptable aqueous composition comprising water, a first sodium hyaluronate fraction having a weight average molecular weight in the range of about 500,000 to about 750,000, and a second sodium hyaluronate fraction having a weight average molecular weight in the range of about 25,000 to about 175,000, said ophthalmically acceptable aqueous composition adhering to at least one portion of the eye in proximity to said natural lens in said eye; causing said natural lens to break into a plurality of particles; removing said plurality of particles; and removing said ophthalmically acceptable aqueous composition from said eye. 10. The method of claim 9 wherein said ophthalmically acceptable aqueous composition further includes at least one buffer component in an amount effective to control the pH of said ophthalmically acceptable aqueous composition and at least one tonicity adjuster component in an amount effective to control the osmolality of said ophthalmically acceptable aqueous composition, said ophthalmically acceptable aqueous composition introduced into said eye of said human or animal being effective to provide superior protection against trauma relative to a similar composition including a single metal hyaluronate fraction having a weight average molecular weight of 3 to 4 million. 11. The method of claim 10 wherein said opthalmically acceptable aqueous composition has a pH in the range of about 7 to about 7.5, and an osmolality in the range of about 250 to about 350 mOsmol/kg, and said second sodium hyaluronate fraction has a weight average molecular weight in the range of about 35,000 to about 150,000. 12. The method of claim 9 wherein the weight ratio of said first sodium hyaluronate fraction to said second sodium hyaluronate fraction in said ophthalmically acceptable aqueous composition is in the range of about 0.25 to about 4, and said first metal hyaluronate fraction is present in said opthalmically acceptable aqueous composition in a concentration of about 5 mg/ml to about 50 mg/ml. 13. A composition comprising water: a first metal hyaluronate fraction having a weight average molecular weight in the range of about 500,000 to about 750,000; a second metal hyaluronate fraction having a weight average molecular weight in the range of about 25,000 to about 175,000; a buffer component in an amount effective to control the pH of said composition; and a tonicity adjuster component in an amount effective to control the osmolality of said composition, said composition being ophthalmically acceptable and being effective when administered in a protective amount to human or animal eye cell layers and tissues prior to exposure of said eye cell layers and tissues to trauma to protect said eye cell layers and tissues against said trauma, said first metal hyaluronate fraction and said second metal hyaluronate fraction each being independently selected from the group consisting of alkali metal hyaluronates, alkaline earth metal hyaluronates and mixtures thereof . 14. The composition of claim 13 wherein said composition provides superior eye cell layer and tissue protection against trauma relative to a similar composition including a single metal hyaluronate fraction having a weight average molecular weight of 3 to 4 million. 15. The composition of claim 13 wherein said composition has a pH in the_range of about 6 to about 8, and an osmolality in the range of about 200 to about 400 mOsmol/kg, and said second metal hyaluronate fraction has a weight average molecular weight in the range of about 35,000 to about 150,000, said composition being sterile and essentially non-pyrogenic. 16. The composition of claim 13 wherein said second metal hyaluronate fraction has a molecular weight in the range of about 30,000 to about 100,000. 17. The composition of claim 13 wherein said first metal hyaluronate fraction and said second metal hyaluronate fraction are each independently selected from the group consisting of sodium hyaluronates, potassium hyaluronates, magnesium hyaluronates, calcium hyaluronates and mixtures thereof. 18. The composition of claim 13 wherein said first metal hyaluronate fraction is a first sodium hyaluronate fraction and said second metal hyaluronate fraction is a second sodium hyaluronate fraction. 19. The composition of claim 13 wherein the weight ratio of said first metal hyaluronate fraction to said second metal hyaluronate fraction in said composition is in the range of about 0.25 to about 4. 20. The composition of claim 19 wherein said first metal hyaluronate fraction is present in said composition in a concentration in the range of about 5 mg/ml to about 50 mg/ml.

Inventors: CHRIST F RICHARD, CHRIST, F., RICHARD
Applicants: ALLERGAN INC, ALLERGAN, INC.
Application year: 1993
Main classification: A61K31
IPC codes: A61K9, A61K31, A61P27